ClinicalTrials.gg
CompletedNCT00002331Updated Jan 16, 2015

The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS

An interventional study of Ethambutol hydrochloride and Clarithromycin in Mycobacterium Avium-intracellular Infection and HIV Infections, sponsored by Abbott. Completed at 18 sites in 2 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.

Primary conditionAcquired Immunodeficiency SyndromeRegistry: HIV InfectionsReclassifiedWhy we changed it
Registry
HIV Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acquired Immunodeficiency Syndrome
Why
  1. The study's title name Acquired Immunodeficiency Syndrome, a narrower term within HIV Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Abbott · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Acquired Immunodeficiency Syndrome by Abbott — none open to participants now, none under way, none of them phase 3. Acquired Immunodeficiency Syndrome · Abbott.

Started
1994
the only one that year
No phase
4 of 14
none open now
Registered
1st of 14
by date

Among the 14 studies in Acquired Immunodeficiency Syndrome by Abbott, this one is the only one that started in 1994, is one of 4 with no phase, and was the 1st registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

None of the 14 studies in Acquired Immunodeficiency Syndrome by Abbott is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Acquired Immunodeficiency Syndrome by Abbott as a file.
02

Study summary

PRIMARY: To assess the tolerability of the combination regimen of clarithromycin plus ethambutol with or without clofazimine in patients with disseminated Mycobacterium avium Complex (dMAC).

SECONDARY: To determine the proportion of patients achieving a sterile blood culture along with the time required to achieve it. To determine the duration of bacteriological response, defined as length of time that blood cultures remain sterile.

03

Conditions studied

  • Mycobacterium Avium-intracellular Infection
  • HIV Infections

Browse trials for

Keywords

  • Mycobacterium avium-intracellular Infection
  • Drug Therapy, Combination
  • Ethambutol
  • Clofazimine
  • Acquired Immunodeficiency Syndrome
  • Clarithromycin
04

In context

Acquired Immunodeficiency Syndrome Reclassified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.

Compared within Acquired Immunodeficiency Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • History of seropositivity.
  • Disseminated MAC.
  • Positive blood culture for MAC within 4 weeks prior to study entry.
  • Consent of parent or guardian if less than 18 years of age.
  • Ability to complete the study.

NOTE:

  • Patients with active opportunistic infections other than dMAC are permitted if dosage and clinical parameters have been stable for 4 weeks prior to enrollment.

Exclusion criteria

Exclusion Criteria

Concurrent Medication:

Excluded:

  • Active therapy with carbamazepine or theophylline, unless investigator agrees to carefully monitor blood levels.
  • Active therapy with drugs other than treatment for disease, except with approval of the sponsor.
  • Concomitant terfenadine (Seldane or Seldane-D) or astemizole (Hismanal).
  • Amikacin.
  • Azithromycin.
  • Capreomycin.
  • Ciprofloxacin.
  • Cycloserine.
  • Ethionamide.
  • Gentamicin.
  • Kanamycin.
  • Levofloxacin.
  • Lomefloxacin.
  • Ofloxacin.
  • Rifampin.
  • Rifabutin.
  • Sparfloxacin.
  • Streptomycin.
  • Any other aminoglycosides, quinolones, and macrolides.

Patients with the following prior conditions are excluded:

History of allergy or to macrolides, ethambutol, or clofazimine.

Prior Medication:

Excluded:

  • Other antimycobacterials, including aminoglycosides, ansamycin (rifabutin), other macrolides (such as clindamycin), quinolones, and rifampin, between screening and study entry.
  • Clarithromycin or azithromycin as prophylaxis or treatment (for any cause) for more than 14 days cumulative within the past 2 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
07

Study locations

18 sites
  • Kaiser Permanente Med Ctr
    Los Angeles, California 90027, United States
  • UCD Med Ctr
    Sacramento, California 95817, United States
  • Kaiser Permanente Med Ctr
    San Francisco, California 94115, United States
  • Santa Clara Valley Med Ctr
    San Jose, California 951282699, United States
  • George Washington Univ Med Ctr
    Washington, District of Columbia 20037, United States
  • Dr Margaret Fischel
    Miami, Florida 33136, United States
  • Saint Joseph's Hosp / Infectious Disease Rsch Institute
    Tampa, Florida 33614, United States
  • Rush Presbyterian - Saint Luke's Med Ctr
    Chicago, Illinois 60612, United States
  • Tulane Univ Med School
    New Orleans, Louisiana 701122699, United States
  • Johns Hopkins Univ School of Medicine
    Baltimore, Maryland 21205, United States
  • Beth Israel Med Ctr
    New York, New York 10003, United States
  • Mount Sinai Med Ctr
    New York, New York 10029, United States
  • Univ of North Carolina School of Medicine
    Chapel Hill, North Carolina 275997215, United States
  • Dr Stephen Hauptman
    Philadelphia, Pennsylvania 19107, United States
  • Vanderbilt Univ School of Medicine
    Nashville, Tennessee 37212, United States
  • Univ of Texas Southwestern Med Ctr of Dallas
    Dallas, Texas 75235, United States
  • Houston Veterans Administration Med Ctr
    Houston, Texas 77030, United States
  • Dr Javier Morales
    Condado San Juan, 00907, Puerto Rico
08

References and documents

Publications

  • Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, Benson CA, Meek K, Siepman N, Craft JC. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS. 1997 Mar;11(3):311-7. doi: 10.1097/00002030-199703110-00008. PubMed 9147422 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1994, a primary completion of Mar 1995 and a completion of Mar 1995. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 1999
First posted
Aug 31, 2001
Start
Jan 1994
Primary completionActual
Mar 1995
CompletionActual
Mar 1995
Last update
Jan 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00002331
Lead sponsor
Abbott
First posted
Aug 31, 2001
Start date
Jan 1994
Primary completion
Mar 1995
Completion
Mar 1995
Last update
Jan 16, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ethambutol · Clarithromycin · Clofazimine

Start the discussion